Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO1009-DP and ABO-CoV.617.2 mRNA Vaccines in Naive Indonesian Adults
NCT05434585Phase 1Unknown
- Sponsor
- Abogen Bioscience
- Start
- Jul 2022
- Primary completion
- Oct 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing ABO1009-DP, ABO-CoV.617.2 and Placebo (3 arms). Primary endpoints: Incidence of solicited adverse events, Incidence of unsolicited adverse events and 1 more. Status: unknown.
02
Drugs
ABO1009-DPABO-CoV.617.2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05434585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05434585.